| Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer K Moore, N Colombo, G Scambia, BG Kim, A Oaknin, M Friedlander, ... New England Journal of Medicine 379 (26), 2495-2505, 2018 | 2382 | 2018 |
| ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up N Colombo, C Creutzberg, F Amant, T Bosse, A González-Martín, ... International Journal of Gynecologic Cancer 26 (1), 2016 | 1884 | 2016 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1657 | 2017 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1591 | 2017 |
| Olaparib plus bevacizumab as first-line maintenance in ovarian cancer I Ray-Coquard, P Pautier, S Pignata, D Pérol, A González-Martín, ... New England Journal of Medicine 381 (25), 2416-2428, 2019 | 1517 | 2019 |
| ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma N Concin, X Matias-Guiu, I Vergote, D Cibula, MR Mirza, S Marnitz, ... International Journal of Gynecologic Cancer 31 (1), 2021 | 1349 | 2021 |
| ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease N Colombo, C Sessa, A Du Bois, J Ledermann, WG McCluggage, ... Annals of Oncology 30 (5), 672-705, 2019 | 1047 | 2019 |
| Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JA Ledermann, FA Raja, C Fotopoulou, A Gonzalez-Martin, N Colombo, ... Annals of oncology 24, vi24-vi32, 2013 | 1046 | 2013 |
| The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer MEL van der Burg, M van Lent, M Buyse, A Kobierska, N Colombo, ... New England Journal of Medicine 332 (10), 629-634, 1995 | 981 | 1995 |
| The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer MEL van der Burg, M van Lent, M Buyse, A Kobierska, N Colombo, ... New England Journal of Medicine 332 (10), 629-634, 1995 | 981 | 1995 |
| Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup MA Bookman, MF Brady, WP McGuire, PG Harper, DS Alberts, ... Journal of clinical oncology 27 (9), 1419, 2009 | 853 | 2009 |
| European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. EA Eisenhauer, WW ten Bokkel Huinink, KD Swenerton, L Gianni, J Myles, ... Journal of clinical Oncology 12 (12), 2654-2666, 1994 | 802 | 1994 |
| European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. EA Eisenhauer, WW ten Bokkel Huinink, KD Swenerton, L Gianni, J Myles, ... Journal of clinical Oncology 12 (12), 2654-2666, 1994 | 802 | 1994 |
| Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up C Marth, F Landoni, S Mahner, M McCormack, A Gonzalez-Martin, ... Annals of Oncology 28, iv72-iv83, 2017 | 777 | 2017 |
| Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up N Colombo, E Preti, F Landoni, S Carinelli, A Colombo, C Marini, C Sessa Annals of oncology 24, vi33-vi38, 2013 | 769 | 2013 |
| Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial AM Oza, D Cibula, AO Benzaquen, C Poole, RHJ Mathijssen, GS Sonke, ... The lancet oncology 16 (1), 87-97, 2015 | 632 | 2015 |
| Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study UA Matulonis, R Shapira-Frommer, AD Santin, AS Lisyanskaya, S Pignata, ... Annals of Oncology 30 (7), 1080-1087, 2019 | 552 | 2019 |
| Pembrolizumab for persistent, recurrent, or metastatic cervical cancer N Colombo, C Dubot, D Lorusso, MV Caceres, K Hasegawa, ... New England Journal of Medicine 385 (20), 1856-1867, 2021 | 544 | 2021 |
| Lenvatinib plus pembrolizumab for advanced endometrial cancer V Makker, N Colombo, A Casado Herráez, AD Santin, E Colomba, ... New England Journal of Medicine 386 (5), 437-448, 2022 | 461 | 2022 |
| Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up N Colombo, S Carinelli, A Colombo, C Marini, D Rollo, C Sessa Annals of oncology 23, vii27-vii32, 2012 | 405 | 2012 |
